Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP)

Frederick S. Kaplan, Mona Al Mukaddam, Robert Pignolo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Fibrodysplasia ossificans progressiva (FOP) is a rare, disabling genetic disorder characterized by episodic soft tissue swelling (flare-ups) that leads to progressive heterotopic ossification and restricted joint mobility. Methods: Here we present the first longitudinal patient-reported mobility assessment (PRMA) in FOP based on a simple evaluation tool. At initial presentation and follow-up (1–11 year span; median: 6 year span), 64 patients (36 females; 28 males) with classic FOP completed a questionnaire designed to rapidly assess mobility at 15 sites (three axial; six upper limb, and six lower limb). In order to validate this instrument, twenty-one of 64 patients (33%) underwent a cumulative analogue joint involvement scale (CAJIS) evaluation by two physicians within six months of their second self-assessment. Results: We found that: 1) mobility changes were episodic and regional, occurring first in the neck and trunk, followed by the upper limbs and finally the lower limbs; 2) interval improvements in mobility did occur, most notably in the lower limbs (18%), and less so in the upper limbs (12%) and trunk (3%), and 3) patient-reported mobility assessments correlate highly (R2 = 0.81) with physician-reported CAJIS evaluations. Conclusion: This is the first longitudinal PRMA in FOP and provides a simple and valid tool that can be used in the design and evaluation of clinical trials in this progressively disabling disease.

Original languageEnglish (US)
Pages (from-to)158-161
Number of pages4
JournalBone
Volume109
DOIs
StatePublished - Apr 1 2018

Fingerprint

Myositis Ossificans
Upper Extremity
Lower Extremity
Joints
Physicians
Heterotopic Ossification
Inborn Genetic Diseases
Neck
Clinical Trials

Keywords

  • ACVR1
  • Fibrodysplasia ossificans progressiva
  • Heterotopic ossification
  • Joint function
  • Patient-reported outcomes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP). / Kaplan, Frederick S.; Al Mukaddam, Mona; Pignolo, Robert.

In: Bone, Vol. 109, 01.04.2018, p. 158-161.

Research output: Contribution to journalArticle

Kaplan, Frederick S. ; Al Mukaddam, Mona ; Pignolo, Robert. / Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP). In: Bone. 2018 ; Vol. 109. pp. 158-161.
@article{cb17e9531f344322a6f68db4cb31a3b6,
title = "Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP)",
abstract = "Background: Fibrodysplasia ossificans progressiva (FOP) is a rare, disabling genetic disorder characterized by episodic soft tissue swelling (flare-ups) that leads to progressive heterotopic ossification and restricted joint mobility. Methods: Here we present the first longitudinal patient-reported mobility assessment (PRMA) in FOP based on a simple evaluation tool. At initial presentation and follow-up (1–11 year span; median: 6 year span), 64 patients (36 females; 28 males) with classic FOP completed a questionnaire designed to rapidly assess mobility at 15 sites (three axial; six upper limb, and six lower limb). In order to validate this instrument, twenty-one of 64 patients (33{\%}) underwent a cumulative analogue joint involvement scale (CAJIS) evaluation by two physicians within six months of their second self-assessment. Results: We found that: 1) mobility changes were episodic and regional, occurring first in the neck and trunk, followed by the upper limbs and finally the lower limbs; 2) interval improvements in mobility did occur, most notably in the lower limbs (18{\%}), and less so in the upper limbs (12{\%}) and trunk (3{\%}), and 3) patient-reported mobility assessments correlate highly (R2 = 0.81) with physician-reported CAJIS evaluations. Conclusion: This is the first longitudinal PRMA in FOP and provides a simple and valid tool that can be used in the design and evaluation of clinical trials in this progressively disabling disease.",
keywords = "ACVR1, Fibrodysplasia ossificans progressiva, Heterotopic ossification, Joint function, Patient-reported outcomes",
author = "Kaplan, {Frederick S.} and {Al Mukaddam}, Mona and Robert Pignolo",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.bone.2017.06.005",
language = "English (US)",
volume = "109",
pages = "158--161",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP)

AU - Kaplan, Frederick S.

AU - Al Mukaddam, Mona

AU - Pignolo, Robert

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Fibrodysplasia ossificans progressiva (FOP) is a rare, disabling genetic disorder characterized by episodic soft tissue swelling (flare-ups) that leads to progressive heterotopic ossification and restricted joint mobility. Methods: Here we present the first longitudinal patient-reported mobility assessment (PRMA) in FOP based on a simple evaluation tool. At initial presentation and follow-up (1–11 year span; median: 6 year span), 64 patients (36 females; 28 males) with classic FOP completed a questionnaire designed to rapidly assess mobility at 15 sites (three axial; six upper limb, and six lower limb). In order to validate this instrument, twenty-one of 64 patients (33%) underwent a cumulative analogue joint involvement scale (CAJIS) evaluation by two physicians within six months of their second self-assessment. Results: We found that: 1) mobility changes were episodic and regional, occurring first in the neck and trunk, followed by the upper limbs and finally the lower limbs; 2) interval improvements in mobility did occur, most notably in the lower limbs (18%), and less so in the upper limbs (12%) and trunk (3%), and 3) patient-reported mobility assessments correlate highly (R2 = 0.81) with physician-reported CAJIS evaluations. Conclusion: This is the first longitudinal PRMA in FOP and provides a simple and valid tool that can be used in the design and evaluation of clinical trials in this progressively disabling disease.

AB - Background: Fibrodysplasia ossificans progressiva (FOP) is a rare, disabling genetic disorder characterized by episodic soft tissue swelling (flare-ups) that leads to progressive heterotopic ossification and restricted joint mobility. Methods: Here we present the first longitudinal patient-reported mobility assessment (PRMA) in FOP based on a simple evaluation tool. At initial presentation and follow-up (1–11 year span; median: 6 year span), 64 patients (36 females; 28 males) with classic FOP completed a questionnaire designed to rapidly assess mobility at 15 sites (three axial; six upper limb, and six lower limb). In order to validate this instrument, twenty-one of 64 patients (33%) underwent a cumulative analogue joint involvement scale (CAJIS) evaluation by two physicians within six months of their second self-assessment. Results: We found that: 1) mobility changes were episodic and regional, occurring first in the neck and trunk, followed by the upper limbs and finally the lower limbs; 2) interval improvements in mobility did occur, most notably in the lower limbs (18%), and less so in the upper limbs (12%) and trunk (3%), and 3) patient-reported mobility assessments correlate highly (R2 = 0.81) with physician-reported CAJIS evaluations. Conclusion: This is the first longitudinal PRMA in FOP and provides a simple and valid tool that can be used in the design and evaluation of clinical trials in this progressively disabling disease.

KW - ACVR1

KW - Fibrodysplasia ossificans progressiva

KW - Heterotopic ossification

KW - Joint function

KW - Patient-reported outcomes

UR - http://www.scopus.com/inward/record.url?scp=85020253033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020253033&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2017.06.005

DO - 10.1016/j.bone.2017.06.005

M3 - Article

C2 - 28600150

AN - SCOPUS:85020253033

VL - 109

SP - 158

EP - 161

JO - Bone

JF - Bone

SN - 8756-3282

ER -